141 related articles for article (PubMed ID: 10373677)
1. Clinical relevance of molecular markers in neuroblastoma: results from a single institution.
Gallego S; Parareda A; Munell F; Sanchez de Toledo J; Reventos J
Oncol Rep; 1999; 6(4):891-6. PubMed ID: 10373677
[TBL] [Abstract][Full Text] [Related]
2. trk A gene expression in neuroblastoma. The clinical significance of an immunohistochemical study.
Tanaka T; Hiyama E; Sugimoto T; Sawada T; Tanabe M; Ida N
Cancer; 1995 Sep; 76(6):1086-95. PubMed ID: 8625212
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of TRKA expression on neuroblastoma: comparison with N-MYC amplification and CD44 expression.
Combaret V; Gross N; Lasset C; Balmas K; Bouvier R; Frappaz D; Beretta-Brognara C; Philip T; Favrot MC; Coll JL
Br J Cancer; 1997; 75(8):1151-5. PubMed ID: 9099963
[TBL] [Abstract][Full Text] [Related]
4. Trk mRNA and low affinity nerve growth factor receptor mRNA expression and triploid DNA content in favorable neuroblastoma tumors.
Kogner P; Barbany G; Björk O; Castello MA; Donfrancesco A; Falkmer UG; Hedborg F; Kouvidou H; Persson H; Raschella G
Prog Clin Biol Res; 1994; 385():137-45. PubMed ID: 7972205
[TBL] [Abstract][Full Text] [Related]
5. Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: a comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening.
Tanaka T; Sugimoto T; Sawada T
Cancer; 1998 Oct; 83(8):1626-33. PubMed ID: 9781958
[TBL] [Abstract][Full Text] [Related]
6. Coexpression of mRNA for the full-length neurotrophin receptor trk-C and trk-A in favourable neuroblastoma.
Svensson T; Rydén M; Schilling FH; Dominici C; Sehgal R; Ibáñez CF; Kogner P
Eur J Cancer; 1997 Oct; 33(12):2058-63. PubMed ID: 9580079
[TBL] [Abstract][Full Text] [Related]
7. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study.
Cohn SL; Look AT; Joshi VV; Holbrook T; Salwen H; Chagnovich D; Chesler L; Rowe ST; Valentine MB; Komuro H
Cancer Res; 1995 Feb; 55(4):721-6. PubMed ID: 7850780
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathology of human neuroblastomas.
Brodeur GM
Semin Diagn Pathol; 1994 May; 11(2):118-25. PubMed ID: 7809505
[TBL] [Abstract][Full Text] [Related]
9. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma.
Nakagawara A; Arima-Nakagawara M; Scavarda NJ; Azar CG; Cantor AB; Brodeur GM
N Engl J Med; 1993 Mar; 328(12):847-54. PubMed ID: 8441429
[TBL] [Abstract][Full Text] [Related]
10. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
Shimada H; Nakagawa A; Peters J; Wang H; Wakamatsu PK; Lukens JN; Matthay KK; Siegel SE; Seeger RC
Cancer; 2004 Oct; 101(8):1873-81. PubMed ID: 15386308
[TBL] [Abstract][Full Text] [Related]
11. [Biological markers for the prognosis of neuroblastoma: proposal of a method of analysis].
Combaret V; Delattre O; Bénard J; Favrot MC
Bull Cancer; 1998 Mar; 85(3):262-6. PubMed ID: 9752317
[TBL] [Abstract][Full Text] [Related]
12. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
13. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas.
Suzuki T; Bogenmann E; Shimada H; Stram D; Seeger RC
J Natl Cancer Inst; 1993 Mar; 85(5):377-84. PubMed ID: 8433391
[TBL] [Abstract][Full Text] [Related]
14. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.
Alvarado CS; London WB; Look AT; Brodeur GM; Altmiller DH; Thorner PS; Joshi VV; Rowe ST; Nash MB; Smith EI; Castleberry RP; Cohn SL
J Pediatr Hematol Oncol; 2000; 22(3):197-205. PubMed ID: 10864050
[TBL] [Abstract][Full Text] [Related]
15. Correlation of MYCN amplification, Trk-A and CD44 expression with clinical stage in 250 patients with neuroblastoma.
Kramer K; Cheung NK; Gerald WL; LaQuaglia M; Kushner BH; LeClerc JM; LeSauter L; Saragovi HU
Eur J Cancer; 1997 Oct; 33(12):2098-100. PubMed ID: 9516861
[TBL] [Abstract][Full Text] [Related]
16. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
18. Reevaluation of trkA expression as a biological marker of neuroblastoma by high-sensitivity expression analysis--a study of 106 primary neuroblastomas treated in a single institute.
Hishiki T; Saito T; Terui K; Sato Y; Takenouchi A; Yahata E; Ono S; Nakagawara A; Kamijo T; Nakamura Y; Matsunaga T; Yoshida H
J Pediatr Surg; 2010 Dec; 45(12):2293-8. PubMed ID: 21129533
[TBL] [Abstract][Full Text] [Related]
19. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.
Look AT; Hayes FA; Shuster JJ; Douglass EC; Castleberry RP; Bowman LC; Smith EI; Brodeur GM
J Clin Oncol; 1991 Apr; 9(4):581-91. PubMed ID: 2066755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
